Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer†
| Autor: | Benjamin Chastek, Stephanie Korrer, Jennifer Malin, Lee N. Newcomer, Thomas Horstman, Stacey DaCosta Byfield |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms 03 medical and health sciences 0302 clinical medicine First line therapy Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Prior authorization Lung cancer Retrospective Studies business.industry Retrospective cohort study General Medicine Middle Aged Prognosis medicine.disease Survival Rate Clinical trial 030104 developmental biology Lymphatic Metastasis 030220 oncology & carcinogenesis Female Non small cell business Value (mathematics) Follow-Up Studies |
| DOI: | 10.6084/m9.figshare.13148341.v1 |
| Popis: | Although physicians rely on clinical trial data to guide cancer treatment decisions, patient characteristics and outcomes often differ between real-world and clinical trial populations. We analyzed retrospective clinical data collected from a prior authorization (PA) tool linked with payer claims data to describe outcomes of first-line treatment for metastatic non-small cell lung cancer among 2,108 patients. Duration of therapy was shorter than observed in clinical trials. Healthcare costs and hospitalizations varied substantially by regimen. PA clinical data linked with administrative claims enable head-to-head comparisons of contemporary cancer treatments used in routine clinical practice, which are not available from clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|